VRDN Viridian Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VRDN

Price (delayed)

$15.4

Market cap

$966.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.31

Enterprise value

$884M

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal ...

Highlights
The equity has soared by 56% QoQ and by 12% YoY
VRDN's quick ratio is up by 41% year-on-year and by 33% since the previous quarter
The net income has plunged by 83% YoY and by 10% from the previous quarter
VRDN's revenue has plunged by 82% YoY and by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.viridiantherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VRDN
Market
Shares outstanding
62.77M
Market cap
$966.62M
Enterprise value
$884M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.83
Price to sales (P/S)
2,195.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,815.28
Earnings
Revenue
$314,000
EBIT
-$235.89M
EBITDA
-$235.32M
Free cash flow
-$185.07M
Per share
EPS
-$5.31
Free cash flow per share
-$4.14
Book value per share
$8.41
Revenue per share
$0.01
TBVPS
$10.96
Balance sheet
Total assets
$490.42M
Total liabilities
$48.4M
Debt
$20.21M
Equity
$442.02M
Working capital
$459.84M
Liquidity
Debt to equity
0.05
Current ratio
18.26
Quick ratio
17.93
Net debt/EBITDA
0.35
Margins
EBITDA margin
-74,941.7%
Gross margin
100%
Net margin
-75,711.5%
Operating margin
-81,035%
Efficiency
Return on assets
-61.1%
Return on equity
-68.3%
Return on invested capital
-85.1%
Return on capital employed
-50.9%
Return on sales
-75,123.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRDN stock price

How has the Viridian Therapeutics stock price performed over time
Intraday
5.62%
1 week
19.57%
1 month
-5.29%
1 year
-44.58%
YTD
-29.29%
QTD
-12.05%

Financial performance

How have Viridian Therapeutics's revenue and profit performed over time
Revenue
$314,000
Gross profit
$314,000
Operating income
-$254.45M
Net income
-$237.73M
Gross margin
100%
Net margin
-75,711.5%
The operating income has dropped by 89% year-on-year and by 10% since the previous quarter
The net income has plunged by 83% YoY and by 10% from the previous quarter
VRDN's revenue has plunged by 82% YoY and by 10% from the previous quarter
VRDN's gross profit has shrunk by 82% YoY and by 10% QoQ

Growth

What is Viridian Therapeutics's growth rate over time

Valuation

What is Viridian Therapeutics stock price valuation
P/E
N/A
P/B
1.83
P/S
2,195.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,815.28
Viridian Therapeutics's EPS has decreased by 31% YoY and by 3.3% QoQ
The equity has soared by 56% QoQ and by 12% YoY
The price to book (P/B) is 35% less than the last 4 quarters average of 2.8 and 3.7% less than the 5-year quarterly average of 1.9
VRDN's revenue has plunged by 82% YoY and by 10% from the previous quarter
The P/S is 38% more than the last 4 quarters average of 1596.0

Efficiency

How efficient is Viridian Therapeutics business performance
The company's return on equity fell by 46% YoY and by 6% QoQ
The return on assets has declined by 44% year-on-year and by 6% since the previous quarter
Viridian Therapeutics's return on sales has decreased by 21% QoQ
Viridian Therapeutics's return on invested capital has increased by 3.6% YoY and by 3.4% QoQ

Dividends

What is VRDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRDN.

Financial health

How did Viridian Therapeutics financials performed over time
Viridian Therapeutics's total assets has increased by 49% QoQ and by 13% YoY
VRDN's quick ratio is up by 41% year-on-year and by 33% since the previous quarter
Viridian Therapeutics's debt is 95% lower than its equity
The equity has soared by 56% QoQ and by 12% YoY
The debt to equity has contracted by 29% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.